| Summary: | 碩士 === 大同大學 === 生物工程學系(所) === 97 === ABSTRACT
Hyaluronic Acid （HA）, residing in soft connective tissue of animal body, is a biopolymer with multi-negative charges. Due to its high biocompatibility, high water contents, unique viscosity, and permeability, HA enables lubrication, protection, support, and other imperative physical functions to organism, and has been comprehensively applied to sticky supplementary substance of joint cavity, cosmetic surgery, ophthalmology, wound healing, anti-adhesion between tissues after operation, drug release, auxiliary disease diagnosis, health products, cosmetics, and industrial fields.
This research introduces patent analysis by the Patent Guider software of Learning Tech. Corp., using various patent indicators and according to classifications of International Patent Classification （IPC）, to explore related technologies of HA with regard to the patent search in the US Patent and Trademark Office for the analysis of the development of patent technologies with regard to HA. According to the analysis, it is found that global HA technology reported a declining position in terms of number of patents; USA is a leading country in HA technology, followed by Italy, the second leading in the world, and Hyal Pharmaceutical from Canada is a company which takes lead in HA patent rights, followed by Fidia Advanced from Italy. Moreover, Fidia Farmaceuti also reported highest number of citations in HA technology, followed by Biomatrix. The patent publication No. 04141973 of Biotrics is the highest cited patent, followed by publication No. 04851521 of Fidia Farmaceuti. Being the best in R&D of HA technology field, the patent investors – Falk and Rudolf Edgar reported the highest number of patents with 27 patents owned in total, with the largest quantity of patents generated between 1996-2001, however, there is no patent generated since 2001; on the contrary, Weigel and Paul, these two investors reported patents from 2003 to now, with 10 patents generated in 2006, and are the most active inventor recently.
According to the 3-level IPC patent classification, USA falls only behind Italy on A61L and is ahead of other countries for the rest of other classifications in terms of number of patents, and is proclaimed as technology leader. If follows 4-level IPC patent classification, A61K031, C08B037 and A61K047HA are ranked top 3 HA patents, respectively. It shows that A-category technology field is highly attended by the enterprises. Hyal Pharmaceutical in A61K, particularly in A61K031, is ahead of other competitors.
Currently, being positioned in a declining stage of HA technology and requiring a breakthrough of study in recent years, it will be riskier for enterprises if they input bulky manpower and resources to develop HA related technologies hastily. Biotrics and Fidia Farmaceuti and other companies that possess key patent rights in HA technology have enabled a threat to other companies or other potential market competitors. However, biomedical materials report a rapid growth in recent years with market potential; therefore, a flexible joint venture or patent authorization manner can be considered by Taiwan to obtain the patent authorization to enable an entry to Mainland China and other new emerging markets, or develop products in niche markets to proceed profound development in different market segments.
|
|---|
